EPC-002 / Elpis Biopharma, Luye Group - LARVOL DELTA

Multi-mechanism human B7H3 CAR-T effectively overcome tumor microenvironment resistance in treatment of solid tumors (AACR 2025) - "EPC-002 is a promising candidate that potentially enhances anti-tumor activity, reduces multiple immunosuppression mechanisms within the TME. These novel mechanisms could potentially translate into durable clinical efficacy for treating solid tumors."

Biomarker • CAR T-Cell Therapy • IO biomarker • Late-breaking abstract • Tumor microenvironment • Hematological Malignancies • Melanoma • Oncology • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • CD276 • IL2

Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore (PRNewswire) - "Elpis Biopharmaceuticals...announced the signing of a Memorandum of Understanding (MOU) with the National Cancer Centre Singapore (NCCS). The partnership aims to support collaborative cell therapy research and clinical trials for the treatment of a variety of cancers, including colorectal, pancreatic and ovarian cancers....As part of the agreement, Elpis will contribute clinically validated technologies for cancer treatment, including multi-mechanism armor, bispecific targeting antibodies, cytokine cocktails, and a rapid mRNA display discovery engine....These technologies are already being investigated in Elpis' global clinical trials of EPC-002 and EPC-003, with the goal of expanding their translational relevance across multiple tumor types."

Licensing / partnership • Colorectal Cancer • Ovarian Cancer • Pancreatic Cancer

Elpis Biopharmaceuticals to Present Two "Late-Breaking" Posters Detailing Its Pioneering CAR-T Cell Therapy Technologies at AACR Annual Meeting 2025 (PRNewswire) - "The first poster...details research involving EPC-002...As presented at AACR, EPC-002 demonstrated an ability to reduce regulatory T cell proliferation, modulate CAR-T and bystander immune cell activation, enhance TIL infiltration, overcome TME suppression, and mediate anti-tumor activity. These mechanisms were highlighted in preclinical mouse models in which EPC-002 enabled complete tumor regression and long-term persistence with very low dose of 0.3M CAR-T cells in tumor rechallenging studies....The second poster...describes the ongoing development of EPC-003....As presented at AACR, in an orthotopic GBM mouse model, EPC-003 induced tumor regression as early as day 6 following intracranial injection of 2 × 10⁶ CAR-T cells. Moreover, intravenous injected CAR-T cells successfully penetrated the BBB, achieving significant tumor regression by day 13 post-treatment."

Preclinical • Glioblastoma • Solid Tumor

Immunogenicity and efficacy analyses of EPC002, ECA006, and EPCP009 protein subunit combinations as tuberculosis vaccine candidates. (PubMed, Vaccine) - "The in vitro mycobacterial growth inhibition assay demonstrated that EPCP009m inhibited Mycobacterium tuberculosis (Mtb) growth most strongly, followed by EPCP009f, which was significantly better than that of the other four vaccine candidates. These results indicated that EPCP009m containing four immunodominant antigens exhibited better immunogenicity and Mtb growth inhibition in vitro and may be a promising candidate vaccine for the control of TB."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • IFNG • IL10 • IL12A • IL17A • IL2 • IL4 • IL6 • TNFA